AU2022244367B2 - Novel cyclopenta[c]pyrrol negative allosteric modulators of nr2b - Google Patents

Novel cyclopenta[c]pyrrol negative allosteric modulators of nr2b Download PDF

Info

Publication number
AU2022244367B2
AU2022244367B2 AU2022244367A AU2022244367A AU2022244367B2 AU 2022244367 B2 AU2022244367 B2 AU 2022244367B2 AU 2022244367 A AU2022244367 A AU 2022244367A AU 2022244367 A AU2022244367 A AU 2022244367A AU 2022244367 B2 AU2022244367 B2 AU 2022244367B2
Authority
AU
Australia
Prior art keywords
pyrrol
hydroxy
phenoxyhexahydrocyclopenta
dihydroquinolin
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU2022244367A
Other languages
English (en)
Other versions
AU2022244367A1 (en
Inventor
Kevin Matthew Gardinier
Mark Patrick Healy
Keith Jendza
Yue Pan
Kate Yaping WANG
Fan Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2022244367A1 publication Critical patent/AU2022244367A1/en
Application granted granted Critical
Publication of AU2022244367B2 publication Critical patent/AU2022244367B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2022244367A 2021-03-26 2022-03-24 Novel cyclopenta[c]pyrrol negative allosteric modulators of nr2b Expired - Fee Related AU2022244367B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166516P 2021-03-26 2021-03-26
US63/166,516 2021-03-26
PCT/US2022/021624 WO2022204336A1 (en) 2021-03-26 2022-03-24 Novel cyclopental[c]pyrrol negative allosteric modulators of nr2b

Publications (2)

Publication Number Publication Date
AU2022244367A1 AU2022244367A1 (en) 2023-09-07
AU2022244367B2 true AU2022244367B2 (en) 2025-04-24

Family

ID=83396075

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022244367A Expired - Fee Related AU2022244367B2 (en) 2021-03-26 2022-03-24 Novel cyclopenta[c]pyrrol negative allosteric modulators of nr2b

Country Status (21)

Country Link
US (1) US20240208953A1 (cg-RX-API-DMAC7.html)
EP (1) EP4313041A4 (cg-RX-API-DMAC7.html)
JP (2) JP7515742B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230160906A (cg-RX-API-DMAC7.html)
CN (1) CN117157072A (cg-RX-API-DMAC7.html)
AR (1) AR125594A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022244367B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023018766A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212203A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023012711A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230458A (cg-RX-API-DMAC7.html)
DO (1) DOP2023000205A (cg-RX-API-DMAC7.html)
EC (1) ECSP23073082A (cg-RX-API-DMAC7.html)
IL (1) IL305601A (cg-RX-API-DMAC7.html)
JO (1) JOP20230236A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023011376A (cg-RX-API-DMAC7.html)
PE (1) PE20250399A1 (cg-RX-API-DMAC7.html)
PY (1) PY2221496A (cg-RX-API-DMAC7.html)
TW (1) TW202304885A (cg-RX-API-DMAC7.html)
UY (1) UY39688A (cg-RX-API-DMAC7.html)
WO (1) WO2022204336A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024387082A1 (en) 2023-11-21 2026-06-04 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048507A1 (en) * 2013-09-26 2015-04-02 Mnemosyne Pharmaceuticals, Inc. Selective octahydro-cyclopenta[c] pyrrole negative modulators of nr2b
WO2016049165A1 (en) * 2014-09-26 2016-03-31 Mnemosyne Pharmaceuticals, Inc. N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627010T3 (es) * 2012-07-19 2017-07-26 Janssen Pharmaceutica, N.V. Antagonistas de octahidro-ciclopentapirrolilo de CCR2
WO2017063563A1 (zh) * 2015-10-13 2017-04-20 四川海思科制药有限公司 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途
CN111481543A (zh) * 2020-05-21 2020-08-04 苏州健雄职业技术学院 Nr2b负变构调节剂联合gaba受体调节剂在制备治疗阿尔兹海默症的药物中的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048507A1 (en) * 2013-09-26 2015-04-02 Mnemosyne Pharmaceuticals, Inc. Selective octahydro-cyclopenta[c] pyrrole negative modulators of nr2b
WO2016049165A1 (en) * 2014-09-26 2016-03-31 Mnemosyne Pharmaceuticals, Inc. N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b

Also Published As

Publication number Publication date
UY39688A (es) 2022-10-31
JP2024509325A (ja) 2024-02-29
PE20250399A1 (es) 2025-02-11
BR112023018766A2 (pt) 2023-10-24
US20240208953A1 (en) 2024-06-27
EP4313041A1 (en) 2024-02-07
JP2024133560A (ja) 2024-10-02
ECSP23073082A (es) 2023-10-31
JP7515742B2 (ja) 2024-07-12
EP4313041A4 (en) 2025-01-15
TW202304885A (zh) 2023-02-01
KR20230160906A (ko) 2023-11-24
CO2023012711A2 (es) 2023-10-19
MX2023011376A (es) 2023-10-06
AU2022244367A1 (en) 2023-09-07
JOP20230236A1 (ar) 2023-09-26
CR20230458A (es) 2023-10-27
PY2221496A (es) 2022-09-29
AR125594A1 (es) 2023-08-02
CN117157072A (zh) 2023-12-01
DOP2023000205A (es) 2023-11-15
WO2022204336A1 (en) 2022-09-29
IL305601A (en) 2023-11-01
CA3212203A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
CN110963994B (zh) 异吲哚啉类化合物、其制备方法、药物组合物及用途
AU2016333721B2 (en) Spiro[3H-indole-3,2´-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-p53 inhibitors
AU2016243939A1 (en) Heterocyclic compounds as LSD1 inhibitors
EP3519393B1 (en) Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors
RS56891B1 (sr) Derivati 2,3-dihidro-benzo[1,4]oksazina i srodna jedinjenja kao inhibitori fosfoinozitid-3-kinaze (pik3) za lečenje, na primer, reumatoidnog artritisa
TW201625617A (zh) 作為mdm2-p53抑制劑之新穎螺-[3h-吲哚-3,2’-吡咯啶]-2(1h)-酮化合物及其衍生物
KR20140095067A (ko) 전압-게이팅 나트륨 채널에서의 선택적 활성을 갖는 벤족사졸리논 화합물
CA3096732A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
TW202446391A (zh) Cyp11b2抑制劑化合物、藥物組合物及其用途
EP3876928A2 (en) Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
TW202134228A (zh) 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
WO2025010255A2 (en) Deuterated organic compounds and uses thereof
CN121925410A (zh) 3-苯基丙胺衍生物
TWI532738B (zh) 作為凝血因子Xa抑制劑的醯肼類化合物
JP7515742B2 (ja) NR2Bの負のアロステリックモジュレーターである新規なシクロペンタ[c]ピロール
CN119390705A (zh) 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物
CA3119882A1 (en) Heterocyclic spiro-compounds as am2 receptor inhibitors
WO2023138412A1 (en) Fused pyrimidin-2-amine compounds as cdk20 inhibitors
CN117120053A (zh) 新的环戊二烯并[c]吡咯NR2B负变构调节剂
ES2378861T3 (es) Derivados de azabiciclo[3.1.0]hexilo como moduladores de los receptores D3 de la dopamina
TWI912370B (zh) 芳香雜環類化合物、藥物組合物及其應用
WO2025240517A1 (en) Cdk4 inhibitor naphthyridine compounds
GB2558975A (en) New compounds
HK1249905B (en) Heterocyclic compounds as lsd1 inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ NOVEL CYCLOPENTA(C)PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B

MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee